NCT03845179 is a NA clinical trial of GIP receptor antagonist in Type2 Diabetes, sponsored by University Hospital, Gentofte, Copenhagen.

Who is sponsoring NCT03845179?

NCT03845179 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT03845179?

Interventions in NCT03845179: Placebo, GIP receptor antagonist, DPP-4 inhibitor, Placebo tablet.

What condition does NCT03845179 study?

NCT03845179 studies Type2 Diabetes.

Is NCT03845179 still recruiting?

NCT03845179 is currently completed. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT03845179

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

Completed NA Last updated 16 March 2021

What this trial tests

NA trial testing Placebo in Type2 Diabetes in 12 participants. Completed in 28 February 2020.

Timeline

29 May 2019

Primary endpoint
28 February 2020

28 February 2020

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	12
Start date	29 May 2019
Primary completion	28 February 2020
Estimated completion	28 February 2020
Sites	1 location across Denmark

Drugs / interventions tested

Placebo
GIP receptor antagonist
DPP-4 inhibitor — full drug profile →
Placebo tablet

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

18 and older, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

57<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes.
· 2021 · cited 11× · PMID 34468792 · DOI 10.1007/s00125-021-05519-y

Verify or expand the search:

Other trials of GIP receptor antagonist

Trials testing the same drug.

NCT03770910 — The Effect of GIP(3-30)NH2 · NA · completed

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03845179 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03845179.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing